Results 221 to 230 of about 65,159 (298)

Two distinct degenerative types of nigrostriatal dopaminergic neuron in the early stage of parkinsonian disorders. [PDF]

Clin Park Relat Disord
Kawazoe T, Sugaya K, Nakata Y, Okitsu M, Takahashi K.   +4 more
europepmc   +1 more source

Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders

, 2019
Sireesha Manne, Naveen Kondru, Monica Hepker, Huajun Jin, Vellareddy Anantharam, Mechelle M. Lewis, Xuemei Huang, Arthi Kanthasamy, Anumantha G. Kanthasamy   +8 more
openalex   +2 more sources

Bifenthrin Under Scrutiny: Revisiting Toxicological Evidence Amid Regulatory Gaps

Journal of Applied Toxicology, Volume 46, Issue 1, Page 61-77, January 2026.
ABSTRACT Despite growing health concerns, bifenthrin (BF) remains widely used for controlling agricultural and residential pests. However, different perspectives on its toxicological profile and regulatory framework warrant a revisit and update on BF regulation towards a robust risk‐safety assessment.
Caroline V. L. Moreira, John Ogbu I, Kadja L. C. Monteiro, Thiago M. de Aquino, Edeildo F. da Silva‐Júnior, Alberto S. S. Filho, Hamilton B. Napolitano, Christianah A. Elusiyan, Renê O. do Couto, Elson A. Costa, James O. Fajemiroye   +10 more
wiley   +1 more source

Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here? [PDF]

Curr Neuropharmacol
Savoie FA, Arpin DJ, Vaillancourt DE.
europepmc   +1 more source

From Molecule to Meaning: Neuronopathic Biomarkers and Clinical Relevance in GM1

Journal of Inherited Metabolic Disease, Volume 49, Issue 1, January 2026.
ABSTRACT GM1 gangliosidosis is a rare, progressively neurodegenerative lysosomal storage disorder characterized by profound central nervous system involvement and substantial clinical heterogeneity. The development of reliable biomarkers is essential for tracking disease progression, stratifying patients, and advancing clinical trial readiness. Primary
Krista Casazza, Roberto Giugliani, Debra S. Regier, Jeanine Jarnes   +3 more
wiley   +1 more source

Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders. [PDF]

Neuroimage Clin, 2020
Stormezand GN, Chaves LT, Vállez García D, Doorduin J, De Jong BM, Leenders KL, Kremer BPH, Dierckx RAJO.   +7 more
europepmc   +1 more source

Levodopa‐Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study

Movement Disorders Clinical Practice, Volume 13, Issue 1, Page 98-107, January 2026.
Abstract Background Dyskinesia is a debilitating complication of dopaminergic therapy in advanced Parkinson's disease. Objectives To evaluate the effect of levodopa‐carbidopa intestinal gel (LCIG) on dyskinesia burden. Methods This is a post hoc analysis of the retrospective, observational COmedication Study assessing Mono‐ and cOmbination therapy with
Alfonso Fasano, Cleanthe Spanaki, Tanya Gurevich, Robert Jech, Per Svenningsson, József Szász, Lydia Vela‐Desojo, Mihaela Simu, Lars Bergmann, Abdallah Saad, Juan Carlos Parra, Norbert Kovács   +11 more
wiley   +1 more source

Rehabilitation of Brain disorders resulting in pathological gait and low quality of life: Focus on Parkinsonian gait [PDF]

, 2018
Matthew O.B. Olaogun, Morenikeji Komolafe, Abiola Oladele Ogundele, A Obembe   +3 more
openalex  

Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders

, 2012
Vikas Kotagal, Martijn L.T.M. Müller, Daniel Kaufer, Robert A. Koeppe, Nicolaas I. Bohnen   +4 more
openalex   +2 more sources